

# Magnus Unemo

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7999597/publications.pdf>

Version: 2024-02-01

415  
papers

21,415  
citations

15504

65  
h-index

15732

125  
g-index

430  
all docs

430  
docs citations

430  
times ranked

9317  
citing authors

#	ARTICLE	IF	CITATIONS
1	Global Estimates of the Prevalence and Incidence of Four Curable Sexually Transmitted Infections in 2012 Based on Systematic Review and Global Reporting. PLoS ONE, 2015, 10, e0143304.	2.5	1,227
2	Chlamydia, gonorrhoea, trichomoniasis and syphilis: global prevalence and incidence estimates, 2016. Bulletin of the World Health Organization, 2019, 97, 548-562P.	3.3	985
3	Antimicrobial Resistance in <i>Neisseria gonorrhoeae</i> in the 21st Century: Past, Evolution, and Future. Clinical Microbiology Reviews, 2014, 27, 587-613.	13.6	894
4	Is <i>Neisseria gonorrhoeae</i> Initiating a Future Era of Untreatable Gonorrhea?: Detailed Characterization of the First Strain with High-Level Resistance to Ceftriaxone. Antimicrobial Agents and Chemotherapy, 2011, 55, 3538-3545.	3.2	600
5	High-Level Cefixime- and Ceftriaxone-Resistant <i>Neisseria gonorrhoeae</i> in France: Novel <i>penA</i> Mosaic Allele in a Successful International Clone Causes Treatment Failure. Antimicrobial Agents and Chemotherapy, 2012, 56, 1273-1280.	3.2	546
6	Sexually transmitted infections: challenges ahead. Lancet Infectious Diseases, The, 2017, 17, e235-e279.	9.1	510
7	Antimicrobial resistance in <i>Neisseria gonorrhoeae</i> : Global surveillance and a call for international collaborative action. PLoS Medicine, 2017, 14, e1002344.	8.4	481
8	2012 European guideline on the diagnosis and treatment of gonorrhoea in adults. International Journal of STD and AIDS, 2013, 24, 85-92.	1.1	371
9	Emergence of multidrug-resistant, extensively drug-resistant and untreatable gonorrhea. Future Microbiology, 2012, 7, 1401-1422.	2.0	367
10	Gonorrhoea. Nature Reviews Disease Primers, 2019, 5, 79.	30.5	284
11	Failure of Dual Antimicrobial Therapy in Treatment of Gonorrhea. New England Journal of Medicine, 2016, 374, 2504-2506.	27.0	283
12	Whole-genome analysis of diverse <i>Chlamydia trachomatis</i> strains identifies phylogenetic relationships masked by current clinical typing. Nature Genetics, 2012, 44, 413-419.	21.4	279
13	Gonorrhoea treatment failure caused by a <i>Neisseria gonorrhoeae</i> strain with combined ceftriaxone and high-level azithromycin resistance, England, February 2018. Eurosurveillance, 2018, 23, .	7.0	255
14	Meeting the public health challenge of multidrug- and extensively drug-resistant <i>Neisseria gonorrhoeae</i> . Expert Review of Anti-Infective Therapy, 2009, 7, 821-834.	4.4	250
15	The novel 2016 WHO <i>Neisseria gonorrhoeae</i> reference strains for global quality assurance of laboratory investigations: phenotypic, genetic and reference genome characterization. Journal of Antimicrobial Chemotherapy, 2016, 71, 3096-3108.	3.0	246
16	2015 European guideline on the management of <i>Chlamydia trachomatis</i> infections. International Journal of STD and AIDS, 2016, 27, 333-348.	1.1	239
17	Current and future antimicrobial treatment of gonorrhoea – the rapidly evolving <i>Neisseria gonorrhoeae</i> continues to challenge. BMC Infectious Diseases, 2015, 15, 364.	2.9	214
18	Phenotypic and genetic characterization of the 2008 WHO <i>Neisseria gonorrhoeae</i> reference strain panel intended for global quality assurance and quality control of gonococcal antimicrobial resistance surveillance for public health purposes. Journal of Antimicrobial Chemotherapy, 2009, 63, 1142-1151.	3.0	208

#	ARTICLE	IF	CITATIONS
19	Neisseria gonorrhoeae Isolates with Reduced Susceptibility to Cefixime and Ceftriaxone: Association with Genetic Polymorphisms in penA , mtrR , porB1b , and ponA. Antimicrobial Agents and Chemotherapy, 2007, 51, 2117-2122.	3.2	186
20	Composition of the Vaginal Microbiota in Women of Reproductive Age – Sensitive and Specific Molecular Diagnosis of Bacterial Vaginosis Is Possible?. PLoS ONE, 2013, 8, e60670.	2.5	184
21	Antimicrobial Resistance Expressed by <i>Neisseria gonorrhoeae</i> : A Major Global Public Health Problem in the 21st Century. Microbiology Spectrum, 2016, 4, .	3.0	178
22	World Health Organization Global Gonococcal Antimicrobial Surveillance Program (WHO GASP): review of new data and evidence to inform international collaborative actions and research efforts. Sexual Health, 2019, 16, 412.	0.9	177
23	Antibiotic resistance in <i>Neisseria gonorrhoeae</i> : origin, evolution, and lessons learned for the future. Annals of the New York Academy of Sciences, 2011, 1230, E19-28.	3.8	174
24	Antimicrobial-resistant sexually transmitted infections: gonorrhoea and Mycoplasma genitalium. Nature Reviews Urology, 2017, 14, 139-152.	3.8	167
25	Public health surveillance of multidrug-resistant clones of Neisseria gonorrhoeae in Europe: a genomic survey. Lancet Infectious Diseases, The, 2018, 18, 758-768.	9.1	164
26	2020 European guideline on the management of syphilis. Journal of the European Academy of Dermatology and Venereology, 2021, 35, 574-588.	2.4	159
27	Prevalence of mutations associated with resistance to macrolides and fluoroquinolones in Mycoplasma genitalium: a systematic review and meta-analysis. Lancet Infectious Diseases, The, 2020, 20, 1302-1314.	9.1	154
28	Should we be testing for urogenital <i>Mycoplasma hominis</i> , <i>Ureaplasma parvum</i> and <i>Ureaplasma urealyticum</i> in men and women? – a position statement from the European STI Guidelines Editorial Board. Journal of the European Academy of Dermatology and Venereology, 2018, 32, 1845-1851.	2.4	148
29	Neisseria gonorrhoeae Sequence Typing for Antimicrobial Resistance, a Novel Antimicrobial Resistance Multilocus Typing Scheme for Tracking Global Dissemination of N. gonorrhoeae Strains. Journal of Clinical Microbiology, 2017, 55, 1454-1468.	3.9	147
30	New Ceftriaxone- and Multidrug-Resistant Neisseria gonorrhoeae Strain with a Novel Mosaic <i>penA</i> Gene Isolated in Japan. Antimicrobial Agents and Chemotherapy, 2016, 60, 4339-4341.	3.2	146
31	Two cases of verified clinical failures using internationally recommended first-line cefixime for gonorrhoea treatment, Norway, 2010. Eurosurveillance, 2010, 15, .	7.0	143
32	Genetics of Chromosomally Mediated Intermediate Resistance to Ceftriaxone and Cefixime in <i>Neisseria gonorrhoeae</i> . Antimicrobial Agents and Chemotherapy, 2009, 53, 3744-3751.	3.2	139
33	Multidrug-resistant gonorrhea: A research and development roadmap to discover new medicines. PLoS Medicine, 2017, 14, e1002366.	8.4	129
34	Review and International Recommendation of Methods for Typing Neisseria gonorrhoeae Isolates and Their Implications for Improved Knowledge of Gonococcal Epidemiology, Treatment, and Biology. Clinical Microbiology Reviews, 2011, 24, 447-458.	13.6	127
35	Genomic Epidemiology and Molecular Resistance Mechanisms of Azithromycin-Resistant Neisseria gonorrhoeae in Canada from 1997 to 2014. Journal of Clinical Microbiology, 2016, 54, 1304-1313.	3.9	124
36	Molecular and Structural Analysis of Mosaic Variants of Penicillin-Binding Protein 2 Conferring Decreased Susceptibility to Expanded-Spectrum Cephalosporins in <i>Neisseria gonorrhoeae</i> : Role of Epistatic Mutations. Biochemistry, 2010, 49, 8062-8070.	2.5	114

#	ARTICLE	IF	CITATIONS
37	WHO global antimicrobial resistance surveillance for <i>Neisseria gonorrhoeae</i> 2017–18: a retrospective observational study. <i>Lancet Microbe</i> , The, 2021, 2, e627-e636.	7.3	112
38	Ceftriaxone treatment failure of pharyngeal gonorrhoea verified by international recommendations, Sweden, July 2010. <i>Eurosurveillance</i> , 2011, 16, .	7.0	111
39	Evaluation of Six Commercial Nucleic Acid Amplification Tests for Detection of <i>Neisseria gonorrhoeae</i> and Other <i>Neisseria</i> Species. <i>Journal of Clinical Microbiology</i> , 2011, 49, 3610-3615.	3.9	110
40	Molecular epidemiological typing within the European Gonococcal Antimicrobial Resistance Surveillance Programme reveals predominance of a multidrug-resistant clone. <i>Eurosurveillance</i> , 2013, 18, .	7.0	110
41	2020 European guideline for the diagnosis and treatment of gonorrhoea in adults. <i>International Journal of STD and AIDS</i> , 2020, , 095646242094912.	1.1	109
42	Phenotypic and genetic characterization of the first two cases of extended-spectrum-cephalosporin-resistant <i>Neisseria gonorrhoeae</i> infection in South Africa and association with cefixime treatment failure. <i>Journal of Antimicrobial Chemotherapy</i> , 2013, 68, 1267-1270.	3.0	108
43	Comprehensive global genome dynamics of <i>Chlamydia trachomatis</i> show ancient diversification followed by contemporary mixing and recent lineage expansion. <i>Genome Research</i> , 2017, 27, 1220-1229.	5.5	106
44	<i>Helicobacter pylori</i> Adapts to Chronic Infection and Gastric Disease via pH-Responsive BabA-Mediated Adherence. <i>Cell Host and Microbe</i> , 2017, 21, 376-389.	11.0	104
45	The Sialic Acid Binding SabA Adhesin of <i>Helicobacter pylori</i> Is Essential for Nonopsonic Activation of Human Neutrophils. <i>Journal of Biological Chemistry</i> , 2005, 280, 15390-15397.	3.4	99
46	Importance of Multidrug Efflux Pumps in the Antimicrobial Resistance Property of Clinical Multidrug-Resistant Isolates of <i>Neisseria gonorrhoeae</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2014, 58, 3556-3559.	3.2	96
47	First <i>Neisseria gonorrhoeae</i> strain with resistance to cefixime causing gonorrhoea treatment failure in Austria, 2011. <i>Eurosurveillance</i> , 2011, 16, .	7.0	96
48	The impact of antimicrobials on gonococcal evolution. <i>Nature Microbiology</i> , 2019, 4, 1941-1950.	13.3	91
49	<i>In Vitro</i> Activity of the New Fluoroketolide Solithromycin (CEM-101) against a Large Collection of Clinical <i>Neisseria gonorrhoeae</i> Isolates and International Reference Strains, Including Those with High-Level Antimicrobial Resistance: Potential Treatment Option for Gonorrhea?. <i>Antimicrobial Agents and Chemotherapy</i> , 2012, 56, 2739-2742.	3.2	90
50	Overall Low Extended-Spectrum Cephalosporin Resistance but high Azithromycin Resistance in <i>Neisseria gonorrhoeae</i> in 24 European Countries, 2015. <i>BMC Infectious Diseases</i> , 2017, 17, 617.	2.9	90
51	Antimicrobial Resistance and Molecular Typing of <i>Neisseria gonorrhoeae</i> Isolates in Kyoto and Osaka, Japan, 2010 to 2012: Intensified Surveillance after Identification of the First Strain (H041) with High-Level Ceftriaxone Resistance. <i>Antimicrobial Agents and Chemotherapy</i> , 2013, 57, 5225-5232.	3.2	88
52	The resurgence of syphilis in high-income countries in the 2000s: a focus on Europe. <i>Epidemiology and Infection</i> , 2019, 147, e143.	2.1	88
53	Diagnosing sexually transmitted infections in resource-constrained settings: challenges and ways forward. <i>Journal of the International AIDS Society</i> , 2019, 22, e25343.	3.0	85
54	Multidrug-resistant <i>Neisseria gonorrhoeae</i> failing treatment with ceftriaxone and doxycycline in France, November 2017. <i>Eurosurveillance</i> , 2018, 23, .	7.0	84

#	ARTICLE	IF	CITATIONS
55	Multidrug-resistant <i>Neisseria gonorrhoeae</i> infection with ceftriaxone resistance and intermediate resistance to azithromycin, Denmark, 2017. <i>Eurosurveillance</i> , 2017, 22, .	7.0	83
56	Proteomics-driven Antigen Discovery for Development of Vaccines Against Gonorrhea. <i>Molecular and Cellular Proteomics</i> , 2016, 15, 2338-2355.	3.8	82
57	The Swedish new variant of <i>Chlamydia trachomatis</i> : genome sequence, morphology, cell tropism and phenotypic characterization. <i>Microbiology (United Kingdom)</i> , 2010, 156, 1394-1404.	1.8	81
58	WGS analysis and molecular resistance mechanisms of azithromycin-resistant (MIC >2) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 627 Td Chemotherapy, 2016, 71, 3109-3116.	3.0	81
59	Time-kill curve analysis and pharmacodynamic modelling for in vitro evaluation of antimicrobials against <i>Neisseria gonorrhoeae</i> . <i>BMC Microbiology</i> , 2016, 16, 216.	3.3	81
60	Emergence, spread and characteristics of <i>Neisseria gonorrhoeae</i> isolates with in vitro decreased susceptibility and resistance to extended-spectrum cephalosporins in Sweden. <i>Sexually Transmitted Infections</i> , 2010, 86, 454-460.	1.9	80
61	Comparison of <i>Staphylococcus epidermidis</i> isolated from prosthetic joint infections and commensal isolates in regard to antibiotic susceptibility, agr type, biofilm production, and epidemiology. <i>International Journal of Medical Microbiology</i> , 2013, 303, 32-39.	3.6	80
62	Multidrug-resistant <i>Neisseria gonorrhoeae</i> isolate, belonging to the internationally spreading Japanese FC428 clone, with ceftriaxone resistance and intermediate resistance to azithromycin, Ireland, August 2018. <i>Eurosurveillance</i> , 2018, 23, .	7.0	80
63	A Novel Mechanism of High-Level, Broad-Spectrum Antibiotic Resistance Caused by a Single Base Pair Change in <i>Neisseria gonorrhoeae</i> . <i>MBio</i> , 2011, 2, .	4.1	77
64	2021 European guideline on the management of <i>Mycoplasma genitalium</i> infections. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2022, 36, 641-650.	2.4	75
65	<i>Neisseria gonorrhoeae</i> Strain with High-Level Resistance to Spectinomycin Due to a Novel Resistance Mechanism (Mutated Ribosomal Protein S5) Verified in Norway. <i>Antimicrobial Agents and Chemotherapy</i> , 2013, 57, 1057-1061.	3.2	74
66	Clinical and analytical evaluation of the new Aptima <i>Mycoplasma genitalium</i> assay, with data on <i>M. genitalium</i> prevalence and antimicrobial resistance in <i>M. genitalium</i> in Denmark, Norway and Sweden in 2016. <i>Clinical Microbiology and Infection</i> , 2018, 24, 533-539.	6.0	74
67	Treatment failure of pharyngeal gonorrhoea with internationally recommended first-line ceftriaxone verified in Slovenia, September 2011. <i>Eurosurveillance</i> , 2012, 17, .	7.0	72
68	Antimicrobial Resistance in <i>Neisseria gonorrhoeae</i> and Treatment of Gonorrhea. <i>Methods in Molecular Biology</i> , 2019, 1997, 37-58.	0.9	71
69	The Swedish new variant of <i>Chlamydia trachomatis</i> . <i>Current Opinion in Infectious Diseases</i> , 2011, 24, 62-69.	3.1	70
70	Analytical Evaluation of GeneXpert CT/NG, the First Genetic Point-of-Care Assay for Simultaneous Detection of <i>Neisseria gonorrhoeae</i> and <i>Chlamydia trachomatis</i> . <i>Journal of Clinical Microbiology</i> , 2013, 51, 1945-1947.	3.9	70
71	Stably high azithromycin resistance and decreasing ceftriaxone susceptibility in <i>Neisseria gonorrhoeae</i> in 25 European countries, 2016. <i>BMC Infectious Diseases</i> , 2018, 18, 609.	2.9	69
72	Population structure of <i>Neisseria gonorrhoeae</i> based on whole genome data and its relationship with antibiotic resistance. <i>PeerJ</i> , 2015, 3, e806.	2.0	67

#	ARTICLE	IF	CITATIONS
73	2019 European guideline on the management of lymphogranuloma venereum. Journal of the European Academy of Dermatology and Venereology, 2019, 33, 1821-1828.	2.4	67
74	Treatment efficacy, treatment failures and selection of macrolide resistance in patients with high load of Mycoplasma genitalium during treatment of male urethritis with josamycin. BMC Infectious Diseases, 2015, 15, 40.	2.9	66
75	An evaluation of gentamicin susceptibility of Neisseria gonorrhoeae isolates in Europe. Journal of Antimicrobial Chemotherapy, 2011, 66, 592-595.	3.0	63
76	<i>In Vitro</i> Activity of Ertapenem versus Ceftriaxone against Neisseria gonorrhoeae Isolates with Highly Diverse Ceftriaxone MIC Values and Effects of Ceftriaxone Resistance Determinants: Ertapenem for Treatment of Gonorrhea?. Antimicrobial Agents and Chemotherapy, 2012, 56, 3603-3609.	3.2	63
77	Emergence and evolution of internationally disseminated cephalosporin-resistant Neisseria gonorrhoeae clones from 1995 to 2005 in Japan. BMC Infectious Diseases, 2015, 15, 378.	2.9	63
78	Frequency and typing of Propionibacterium acnes in prostate tissue obtained from men with and without prostate cancer. Infectious Agents and Cancer, 2016, 11, 26.	2.6	63
79	A community-driven resource for genomic epidemiology and antimicrobial resistance prediction of Neisseria gonorrhoeae at Pathogenwatch. Genome Medicine, 2021, 13, 61.	8.2	63
80	High <i>In Vitro</i> Activity of the Novel Spiropyrimidinetrione AZD0914, a DNA Gyrase Inhibitor, against Multidrug-Resistant Neisseria gonorrhoeae Isolates Suggests a New Effective Option for Oral Treatment of Gonorrhea. Antimicrobial Agents and Chemotherapy, 2014, 58, 5585-5588.	3.2	62
81	First Neisseria gonorrhoeae strain with resistance to cefixime causing gonorrhoea treatment failure in Austria, 2011. Eurosurveillance, 2011, 16, .	7.0	62
82	Total Variation in the penA Gene of Neisseria meningitidis : Correlation between Susceptibility to $\beta$ -Lactam Antibiotics and penA Gene Heterogeneity. Antimicrobial Agents and Chemotherapy, 2006, 50, 3317-3324.	3.2	61
83	Recent advances in the development and use of molecular tests to predict antimicrobial resistance in <i>Neisseria gonorrhoeae</i> . Expert Review of Molecular Diagnostics, 2017, 17, 845-859.	3.1	61
84	Ceftriaxone treatment failure of pharyngeal gonorrhoea verified by international recommendations, Sweden, July 2010. Eurosurveillance, 2011, 16, .	7.0	60
85	A Fast Real-Time Polymerase Chain Reaction Method for Sensitive and Specific Detection of the Neisseria gonorrhoeae porA Pseudogene. Journal of Molecular Diagnostics, 2006, 8, 574-581.	2.8	59
86	<i>In Vitro</i> Activity of the New Fluoroketolide Solithromycin (CEM-101) against Macrolide-Resistant and -Susceptible Mycoplasma genitalium Strains. Antimicrobial Agents and Chemotherapy, 2014, 58, 3151-3156.	3.2	59
87	Antimicrobial resistance prediction and phylogenetic analysis of Neisseria gonorrhoeae isolates using the Oxford Nanopore MinION sequencer. Scientific Reports, 2018, 8, 17596.	3.3	59
88	Reproductive tract infections including sexually transmitted infections: a population-based study of women of reproductive age in a rural district of Vietnam. Sexually Transmitted Infections, 2008, 84, 126-132.	1.9	58
89	Identification of Amino Acids Conferring High-Level Resistance to Expanded-Spectrum Cephalosporins in the <i>penA</i> Gene from Neisseria gonorrhoeae Strain H041. Antimicrobial Agents and Chemotherapy, 2013, 57, 3029-3036.	3.2	58
90	Plasmid deficiency in urogenital isolates of <i>Chlamydia trachomatis</i> reduces infectivity and virulence in a mouse model. Pathogens and Disease, 2014, 70, 61-69.	2.0	58

#	ARTICLE	IF	CITATIONS
91	Characterisation of bla TEM genes and types of $\beta$ -lactamase plasmids in <i>Neisseria gonorrhoeae</i> – the prevalent and conserved bla TEM-135 has not recently evolved and existed in the Toronto plasmid from the origin. <i>BMC Infectious Diseases</i> , 2014, 14, 454.	2.9	57
92	Genomic evolution of <i>Neisseria gonorrhoeae</i> since the preantibiotic era (1928–2013): antimicrobial use/misuse selects for resistance and drives evolution. <i>BMC Genomics</i> , 2020, 21, 116.	2.8	57
93	Molecular Diagnostics for Gonorrhoea: Implications for Antimicrobial Resistance and the Threat of Untreatable Gonorrhoea. <i>PLoS Medicine</i> , 2014, 11, e1001598.	8.4	56
94	First Three <i>Neisseria gonorrhoeae</i> Isolates with High-Level Resistance to Azithromycin in Sweden: a Threat to Currently Available Dual-Antimicrobial Regimens for Treatment of Gonorrhoea?. <i>Antimicrobial Agents and Chemotherapy</i> , 2014, 58, 624-625.	3.2	56
95	Pharmacokinetic considerations regarding the treatment of bacterial sexually transmitted infections with azithromycin: a review. <i>Journal of Antimicrobial Chemotherapy</i> , 2019, 74, 1157-1166.	3.0	56
96	Molecular epidemiological typing within the European Gonococcal Antimicrobial Resistance Surveillance Programme reveals predominance of a multidrug-resistant clone. <i>Eurosurveillance</i> , 2013, 18, .	7.0	55
97	Antimicrobial susceptibility and genetic characteristics of <i>Neisseria gonorrhoeae</i> isolates from Vietnam, 2011. <i>BMC Infectious Diseases</i> , 2013, 13, 40.	2.9	54
98	The serious threat of multidrug-resistant and untreatable gonorrhoea: the pressing need for global action to control the spread of antimicrobial resistance, and mitigate the impact on sexual and reproductive health. <i>Sexually Transmitted Infections</i> , 2012, 88, 317-318.	1.9	53
99	Utilizing CMP-Sialic Acid Analogs to Unravel <i>Neisseria gonorrhoeae</i> Lipooligosaccharide-Mediated Complement Resistance and Design Novel Therapeutics. <i>PLoS Pathogens</i> , 2015, 11, e1005290.	4.7	53
100	Molecular tests for the detection of antimicrobial resistant <i>Neisseria gonorrhoeae</i> . <i>Current Opinion in Infectious Diseases</i> , 2016, 29, 45-51.	3.1	51
101	In Vivo -Selected Compensatory Mutations Restore the Fitness Cost of Mosaic penA Alleles That Confer Ceftriaxone Resistance in <i>Neisseria gonorrhoeae</i> . <i>MBio</i> , 2018, 9, .	4.1	51
102	Adaptation to the cervical environment is associated with increased antibiotic susceptibility in <i>Neisseria gonorrhoeae</i> . <i>Nature Communications</i> , 2020, 11, 4126.	12.8	51
103	Global phylogeny of <i>Treponema pallidum</i> lineages reveals recent expansion and spread of contemporary syphilis. <i>Nature Microbiology</i> , 2021, 6, 1549-1560.	13.3	51
104	In vitro activity of the novel triazaacenaphthylene gepotidacin (GSK2140944) against MDR <i>Neisseria gonorrhoeae</i> . <i>Journal of Antimicrobial Chemotherapy</i> , 2018, 73, 2072-2077.	3.0	50
105	Clonal expansion and spread of the ceftriaxone-resistant <i>Neisseria gonorrhoeae</i> strain FC428, identified in Japan in 2015, and closely related isolates. <i>Journal of Antimicrobial Chemotherapy</i> , 2019, 74, 1812-1819.	3.0	50
106	Four treatment failures of pharyngeal gonorrhoea with ceftriaxone (500 mg) or cefotaxime (500 mg), Sweden, 2013 and 2014. <i>Eurosurveillance</i> , 2014, 19, .	7.0	49
107	<i>In Vitro</i> Activity of the Novel Pleuromutilin Lefamulin (BC-3781) and Effect of Efflux Pump Inactivation on Multidrug-Resistant and Extensively Drug-Resistant <i>Neisseria gonorrhoeae</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2017, 61, .	3.2	48
108	First nationwide study regarding ceftriaxone resistance and molecular epidemiology of <i>Neisseria gonorrhoeae</i> in China. <i>Journal of Antimicrobial Chemotherapy</i> , 2016, 71, 92-99.	3.0	47

#	ARTICLE	IF	CITATIONS
109	Treatment failure of pharyngeal gonorrhoea with internationally recommended first-line ceftriaxone verified in Slovenia, September 2011. <i>Eurosurveillance</i> , 2012, 17, .	7.0	47
110	Molecular Epidemiology of <i>Neisseria gonorrhoeae</i> : Sequence Analysis of the porB Gene Confirms Presence of Two Circulating Strains. <i>Journal of Clinical Microbiology</i> , 2002, 40, 3741-3749.	3.9	46
111	Molecular Analyses of TEM Genes and Their Corresponding Penicillinase-Producing <i>Neisseria gonorrhoeae</i> Isolates in Bangkok, Thailand. <i>Antimicrobial Agents and Chemotherapy</i> , 2012, 56, 916-920.	3.2	46
112	Evaluation of the new AmpliSens multiplex real-time PCR assay for simultaneous detection of <i>Neisseria gonorrhoeae</i> , <i>Chlamydia trachomatis</i> , <i>Mycoplasma genitalium</i> , and <i>Trichomonas vaginalis</i> . <i>Apmis</i> , 2015, 123, 879-886.	2.0	46
113	Systematic reviews of point-of-care tests for the diagnosis of urogenital <i>Chlamydia trachomatis</i> infections. <i>Sexually Transmitted Infections</i> , 2017, 93, S22-S30.	1.9	46
114	Gonococcal vaccines: Public health value and preferred product characteristics; report of a WHO global stakeholder consultation, January 2019. <i>Vaccine</i> , 2020, 38, 4362-4373.	3.8	46
115	Molecular genetic methods for diagnosis and characterisation of <i>Chlamydia trachomatis</i> and <i>Neisseria gonorrhoeae</i> : impact on epidemiological surveillance and interventions. <i>Apmis</i> , 2004, 112, 771-784.	2.0	45
116	Molecular characterization of <i>Neisseria gonorrhoeae</i> identifies transmission and resistance of one ciprofloxacin-resistant strain. <i>Apmis</i> , 2007, 115, 231-241.	2.0	45
117	<i>In Vitro</i> Activity of Fosfomycin Alone and in Combination with Ceftriaxone or Azithromycin against Clinical <i>Neisseria gonorrhoeae</i> Isolates. <i>Antimicrobial Agents and Chemotherapy</i> , 2015, 59, 1605-1611.	3.2	45
118	WHO laboratory validation of Xpert <sup>®</sup> CT/NG and Xpert <sup>®</sup> TV on the GeneXpert system verifies high performances. <i>Apmis</i> , 2018, 126, 907-912.	2.0	45
119	The Russian gonococcal antimicrobial susceptibility programme (RU-GASP) – national resistance prevalence in 2007 and 2008, and trends during 2005-2008. <i>Eurosurveillance</i> , 2010, 15, .	7.0	45
120	Genetic Resistance Determinants, In Vitro Time-Kill Curve Analysis and Pharmacodynamic Functions for the Novel Topoisomerase II Inhibitor ETX0914 (AZD0914) in <i>Neisseria gonorrhoeae</i> . <i>Frontiers in Microbiology</i> , 2015, 6, 1377.	3.5	44
121	Is the tide turning again for cephalosporin resistance in <i>Neisseria gonorrhoeae</i> in Europe? Results from the 2013 European surveillance. <i>BMC Infectious Diseases</i> , 2015, 15, 321.	2.9	44
122	Decreased susceptibility to chlorhexidine and prevalence of disinfectant resistance genes among clinical isolates of <i>Staphylococcus epidermidis</i> . <i>Apmis</i> , 2014, 122, 961-967.	2.0	43
123	High <i>In Vitro</i> Susceptibility to the Novel Spiropyrimidinetrione ETX0914 (AZD0914) among 873 Contemporary Clinical <i>Neisseria gonorrhoeae</i> Isolates from 21 European Countries from 2012 to 2014. <i>Antimicrobial Agents and Chemotherapy</i> , 2015, 59, 5220-5225.	3.2	42
124	The 2012 European guideline on the diagnosis and treatment of gonorrhoea in adults™ recommends dual antimicrobial therapy. <i>Eurosurveillance</i> , 2012, 17, .	7.0	41
125	The European Gonococcal Antimicrobial Surveillance Programme (Euro-GASP) – a sentinel approach in the European Union (EU)/European Economic Area (EEA). <i>Sexually Transmitted Infections</i> , 2013, 89, iv16-iv18.	1.9	39
126	Alanine 501 Mutations in Penicillin-Binding Protein 2 from <i>Neisseria gonorrhoeae</i> : Structure, Mechanism, and Effects on Cephalosporin Resistance and Biological Fitness. <i>Biochemistry</i> , 2017, 56, 1140-1150.	2.5	39



#	ARTICLE	IF	CITATIONS
127	Performance and operational characteristics of point-of-care tests for the diagnosis of urogenital gonococcal infections. <i>Sexually Transmitted Infections</i> , 2017, 93, S16-S21.	1.9	39
128	Prevalence of macrolide and fluoroquinolone resistance-mediating mutations in <i>Mycoplasma genitalium</i> in five cities in Russia and Estonia. <i>PLoS ONE</i> , 2017, 12, e0175763.	2.5	39
129	First nationwide antimicrobial susceptibility surveillance for <i>Neisseria gonorrhoeae</i> in Brazil, 2015-2016. <i>Journal of Antimicrobial Chemotherapy</i> , 2018, 73, 1854-1861.	3.0	39
130	Call to action for health systems integration of point-of-care testing to mitigate the transmission and burden of sexually transmitted infections. <i>Sexually Transmitted Infections</i> , 2020, 96, 342-347.	1.9	39
131	Initial impacts of the COVID-19 pandemic on sexual and reproductive health service use and unmet need in Britain: findings from a quasi-representative survey (Natsal-COVID). <i>Lancet Public Health</i> , The, 2022, 7, e36-e47.	10.0	39
132	Alterations of the pilQ gene in <i>Neisseria gonorrhoeae</i> are unlikely contributors to decreased susceptibility to ceftriaxone and cefixime in clinical gonococcal strains. <i>Journal of Antimicrobial Chemotherapy</i> , 2010, 65, 2543-2547.	3.0	38
133	Rapid accurate point-of-care tests combining diagnostics and antimicrobial resistance prediction for <i>Neisseria gonorrhoeae</i> and <i>Mycoplasma genitalium</i> . <i>Sexually Transmitted Infections</i> , 2017, 93, S65-S68.	1.9	38
134	Quantitation of all Four <i>Gardnerella vaginalis</i> Clades Detects Abnormal Vaginal Microbiota Characteristic of Bacterial Vaginosis More Accurately than Putative <i>G. Vaginalis</i> Sialidase Gene Count. <i>Molecular Diagnosis and Therapy</i> , 2019, 23, 139-147.	3.8	38
135	Connector Inversion Probe Technology: A Powerful One-Primer Multiplex DNA Amplification System for Numerous Scientific Applications. <i>PLoS ONE</i> , 2007, 2, e915.	2.5	38
136	Antibiotic susceptibility of <i>Propionibacterium acnes</i> isolated from orthopaedic implant-associated infections. <i>Anaerobe</i> , 2015, 32, 57-62.	2.1	37
137	<i>Neisseria cinerea</i> with High Ceftriaxone MIC Is a Source of Ceftriaxone and Cefixime Resistance-Mediating <i>penA</i> Sequences in <i>Neisseria gonorrhoeae</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2018, 62, .	3.2	37
138	Population-Level Antimicrobial Consumption Is Associated With Decreased Antimicrobial Susceptibility in <i>Neisseria gonorrhoeae</i> in 24 European Countries: An Ecological Analysis. <i>Journal of Infectious Diseases</i> , 2020, 221, 1107-1116.	4.0	37
139	One year of <i>Neisseria gonorrhoeae</i> isolates in Sweden: the prevalence study of antibiotic susceptibility shows relation to the geographic area of exposure. <i>International Journal of STD and AIDS</i> , 2002, 13, 109-114.	1.1	36
140	Antimicrobial resistance and molecular epidemiology using whole-genome sequencing of <i>Neisseria gonorrhoeae</i> in Ireland, 2014-2016: focus on extended-spectrum cephalosporins and azithromycin. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 2018, 37, 1661-1672.	2.9	36
141	Current and future treatment options for gonorrhoea: Table 1. <i>Sexually Transmitted Infections</i> , 2013, 89, iv52-iv56.	1.9	35
142	Antimicrobial resistance, genetic resistance determinants for ceftriaxone and molecular epidemiology of <i>Neisseria gonorrhoeae</i> isolates in Nanjing, China. <i>Journal of Antimicrobial Chemotherapy</i> , 2014, 69, 2959-2965.	3.0	35
143	A Novel Factor H Chimeric Immunotherapeutic Molecule against <i>Neisseria gonorrhoeae</i> . <i>Journal of Immunology</i> , 2016, 196, 1732-1740.	0.8	35
144	<i>Mycoplasma genitalium</i> : whole genome sequence analysis, recombination and population structure. <i>BMC Genomics</i> , 2017, 18, 993.	2.8	35

#	ARTICLE	IF	CITATIONS
145	Quantitative Proteomics of the 2016 WHO Neisseria gonorrhoeae Reference Strains Surveys Vaccine Candidates and Antimicrobial Resistance Determinants. <i>Molecular and Cellular Proteomics</i> , 2019, 18, 127-150.	3.8	35
146	Extensively drug-resistant (XDR) Neisseria gonorrhoeae causing possible gonorrhoea treatment failure with ceftriaxone plus azithromycin in Austria, April 2022. <i>Eurosurveillance</i> , 2022, 27, .	7.0	35
147	Gonorrhoea and gonococcal antimicrobial resistance surveillance networks in the WHO European Region, including the independent countries of the former Soviet Union. <i>Sexually Transmitted Infections</i> , 2013, 89, iv42-iv46.	1.9	34
148	Comparison of Serologic and Genetic porB -Based Typing of Neisseria gonorrhoeae : Consequences for Future Characterization. <i>Journal of Clinical Microbiology</i> , 2003, 41, 4141-4147.	3.9	33
149	Evolution of <i>Neisseria gonorrhoeae</i> is a continuing challenge for molecular detection of gonorrhoea: false negative gonococcal porA mutants are spreading internationally. <i>Sexually Transmitted Infections</i> , 2013, 89, 197-201.	1.9	33
150	Phenotypic and molecular characterization of Neisseria gonorrhoeae isolates from Slovenia, 2006-12: rise and fall of the multidrug-resistant NG-MAST genogroup 1407 clone?. <i>Journal of Antimicrobial Chemotherapy</i> , 2014, 69, 1517-1525.	3.0	33
151	Risk Factors for Antimicrobial-Resistant Neisseria gonorrhoeae in Europe. <i>Sexually Transmitted Diseases</i> , 2014, 41, 723-729.	1.7	33
152	Emergence of decreased susceptibility and resistance to extended-spectrum cephalosporins in <i>Neisseria gonorrhoeae</i> in Korea. <i>Journal of Antimicrobial Chemotherapy</i> , 2015, 70, 2536-2542.	3.0	33
153	Multiplex Real-Time PCR Assay with High-Resolution Melting Analysis for Characterization of Antimicrobial Resistance in Neisseria gonorrhoeae. <i>Journal of Clinical Microbiology</i> , 2016, 54, 2074-2081.	3.9	33
154	Genome-based epidemiology and antimicrobial resistance determinants of Neisseria gonorrhoeae isolates with decreased susceptibility and resistance to extended-spectrum cephalosporins in Argentina in 2011-16. <i>Journal of Antimicrobial Chemotherapy</i> , 2019, 74, 1551-1559.	3.0	33
155	Pharmacokinetic Data Are Predictive of <i>In Vivo</i> Efficacy for Cefixime and Ceftriaxone against Susceptible and Resistant <i>Neisseria gonorrhoeae</i> Strains in the Gonorrhea Mouse Model. <i>Antimicrobial Agents and Chemotherapy</i> , 2019, 63, .	3.2	33
156	Antibiotic Susceptibility and Characteristics of <i>Neisseria meningitidis</i> Isolates from the African Meningitis Belt, 2000 to 2006: Phenotypic and Genotypic Perspectives. <i>Antimicrobial Agents and Chemotherapy</i> , 2009, 53, 1561-1566.	3.2	32
157	Characterisation of Chlamydia trachomatis by ompA sequencing and multilocus sequence typing in a Swedish county before and after identification of the new variant. <i>Sexually Transmitted Infections</i> , 2010, 86, 56-60.	1.9	32
158	A new rapid resazurin-based microdilution assay for antimicrobial susceptibility testing of Neisseria gonorrhoeae. <i>Journal of Antimicrobial Chemotherapy</i> , 2017, 72, 1961-1968.	3.0	32
159	The European gonococcal antimicrobial surveillance programme, 2009. <i>Eurosurveillance</i> , 2011, 16, .	7.0	32
160	Experiences with the new genetic variant of Chlamydia trachomatis in Årbro county, Sweden – proportion, characteristics and effective diagnostic solution in an emergent situation. <i>Eurosurveillance</i> , 2007, 12, 5-6.	7.0	32
161	Genome Sequencing of a Neisseria gonorrhoeae Isolate of a Successful International Clone with Decreased Susceptibility and Resistance to Extended-Spectrum Cephalosporins. <i>Antimicrobial Agents and Chemotherapy</i> , 2012, 56, 5633-5641.	3.2	31
162	Novel meningococcal 4CMenB vaccine antigens – prevalence and polymorphisms of the encoding genes in <i>Neisseria gonorrhoeae</i> . <i>Apmsis</i> , 2012, 120, 750-760.	2.0	31

#	ARTICLE	IF	CITATIONS
163	In vitro activity of zoliflodacin (ETX0914) against macrolide-resistant, fluoroquinolone-resistant and antimicrobial-susceptible <i>Mycoplasma genitalium</i> strains. <i>Journal of Antimicrobial Chemotherapy</i> , 2018, 73, 1291-1294.	3.0	31
164	Bacterial vaginosis-associated vaginal microbiota is an age-independent risk factor for <i>Chlamydia trachomatis</i> , <i>Mycoplasma genitalium</i> and <i>Trichomonas vaginalis</i> infections in low-risk women, St. Petersburg, Russia. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 2020, 39, 1221-1230.	2.9	31
165	High susceptibility to zoliflodacin and conserved target (GyrB) for zoliflodacin among 1209 consecutive clinical <i>Neisseria gonorrhoeae</i> isolates from 25 European countries, 2018. <i>Journal of Antimicrobial Chemotherapy</i> , 2021, 76, 1221-1228.	3.0	31
166	First evaluation of six nucleic acid amplification tests widely used in the diagnosis of <i>Chlamydia trachomatis</i> in Russia. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2009, 23, 268-276.	2.4	30
167	Challenges with gonorrhoea in the era of multi-drug and extensively drug resistance “are we on the right track?”. <i>Expert Review of Anti-Infective Therapy</i> , 2014, 12, 653-656.	4.4	30
168	Dual antimicrobial therapy for gonorrhoea: what is the role of azithromycin?. <i>Lancet Infectious Diseases</i> , The, 2018, 18, 486-488.	9.1	30
169	Gonorrhoea: a systematic review of prevalence reporting globally. <i>BMC Infectious Diseases</i> , 2021, 21, 1152.	2.9	30
170	Global transmission of prolyliminopeptidase-negative <i>Neisseria gonorrhoeae</i> strains: implications for changes in diagnostic strategies. <i>Sexually Transmitted Infections</i> , 2006, 83, 47-51.	1.9	29
171	<i>Neisseria gonorrhoeae</i> population in Arkhangelsk, Russia: phenotypic and genotypic heterogeneity. <i>Clinical Microbiology and Infection</i> , 2007, 13, 873-878.	6.0	29
172	HIV, STI prevalence and risk behaviours among women selling sex in Lahore, Pakistan. <i>BMC Infectious Diseases</i> , 2011, 11, 119.	2.9	29
173	Antimicrobial susceptibility/resistance and NG-MAST characterisation of <i>Neisseria gonorrhoeae</i> in Belarus, Eastern Europe, 2010–2013. <i>BMC Infectious Diseases</i> , 2015, 15, 29.	2.9	29
174	Genomic epidemiology of <i>Neisseria gonorrhoeae</i> elucidating the gonococcal antimicrobial resistance and lineages/sublineages across Brazil, 2015–16. <i>Journal of Antimicrobial Chemotherapy</i> , 2020, 75, 3163-3172.	3.0	29
175	Recommended antimicrobial treatment of uncomplicated gonorrhoea in 2009 in 11 East European countries: implementation of a <i>Neisseria gonorrhoeae</i> antimicrobial susceptibility programme in this region is crucial. <i>Sexually Transmitted Infections</i> , 2010, 86, 442-444.	1.9	28
176	Innate Recognition by Neutrophil Granulocytes Differs between <i>Neisseria gonorrhoeae</i> Strains Causing Local or Disseminating Infections. <i>Infection and Immunity</i> , 2013, 81, 2358-2370.	2.2	28
177	Russian gonococcal antimicrobial susceptibility programme (RU-CASP) “resistance in <i>Neisseria gonorrhoeae</i> during 2009–2012 and NG-MAST genotypes in 2011 and 2012. <i>BMC Infectious Diseases</i> , 2014, 14, 342.	2.9	28
178	Genomic analysis and antimicrobial resistance of <i>Neisseria gonorrhoeae</i> isolates from Vietnam in 2011 and 2015–16. <i>Journal of Antimicrobial Chemotherapy</i> , 2020, 75, 1432-1438.	3.0	28
179	Clonally Related <i>Neisseria gonorrhoeae</i> Isolates with Decreased Susceptibility to the Extended-Spectrum Cephalosporin Cefotaxime in Amsterdam, the Netherlands. <i>Antimicrobial Agents and Chemotherapy</i> , 2012, 56, 1516-1522.	3.2	27
180	Test of Cure for Anogenital Gonorrhoea Using Modern RNA-Based and DNA-Based Nucleic Acid Amplification Tests: A Prospective Cohort Study. <i>Clinical Infectious Diseases</i> , 2016, 62, 1348-1355.	5.8	27

#	ARTICLE	IF	CITATIONS
181	The European gonococcal antimicrobial surveillance programme (Euro-GASP) appropriately reflects the antimicrobial resistance situation for <i>Neisseria gonorrhoeae</i> in the European Union/European Economic Area. <i>BMC Infectious Diseases</i> , 2019, 19, 1040.	2.9	27
182	Optimising treatments for sexually transmitted infections: surveillance, pharmacokinetics and pharmacodynamics, therapeutic strategies, and molecular resistance prediction. <i>Lancet Infectious Diseases</i> , The, 2020, 20, e181-e191.	9.1	27
183	Analysis of PorA variable region 3 in meningococci: implications for vaccine policy?. <i>Vaccine</i> , 2003, 21, 2468-2473.	3.8	26
184	National surveillance of antimicrobial susceptibility in <i>Neisseria gonorrhoeae</i> in 2005-2006 and recommendations of first-line antimicrobial drugs for gonorrhoea treatment in Russia. <i>Sexually Transmitted Infections</i> , 2008, 84, 285-289.	1.9	26
185	Treatment failure with 2 g of azithromycin (extended-release formulation) in gonorrhoea in Japan caused by the international multidrug-resistant ST1407 strain of <i>Neisseria gonorrhoeae</i> . <i>Journal of Antimicrobial Chemotherapy</i> , 2014, 69, 2086-2090.	3.0	26
186	Mismatch Amplification Mutation Assay-Based Real-Time PCR for Rapid Detection of <i>Neisseria gonorrhoeae</i> and Antimicrobial Resistance Determinants in Clinical Specimens. <i>Journal of Clinical Microbiology</i> , 2018, 56, .	3.9	26
187	Emerging cephalosporin and multidrug-resistant gonorrhoea in Europe. <i>Eurosurveillance</i> , 2014, 19, 20955.	7.0	26
188	Molecular Typing of <i>Neisseria gonorrhoeae</i> Isolates by Pyrosequencing of Highly Polymorphic Segments of the <i>porB</i> Gene. <i>Journal of Clinical Microbiology</i> , 2004, 42, 2926-2934.	3.9	25
189	Guidelines for the laboratory diagnosis of trichomoniasis in East European countries. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2010, 24, 1125-1134.	2.4	25
190	Genome-Based Characterization of Emergent Invasive <i>Neisseria meningitidis</i> Serogroup Y Isolates in Sweden from 1995 to 2012. <i>Journal of Clinical Microbiology</i> , 2015, 53, 2154-2162.	3.9	25
191	Detailed characterization of the first high-level azithromycin-resistant <i>Neisseria gonorrhoeae</i> cases in Ireland. <i>Journal of Antimicrobial Chemotherapy</i> , 2015, 70, 2411-2413.	3.0	25
192	Gentamicin 240 mg plus azithromycin 2 g vs. ceftriaxone 500 mg plus azithromycin 2 g for treatment of rectal and pharyngeal gonorrhoea: a randomized controlled trial. <i>Clinical Microbiology and Infection</i> , 2020, 26, 207-212.	6.0	25
193	Guidelines for the Laboratory Diagnosis of <i>Mycoplasma genitalium</i> Infections in East European Countries. <i>Acta Dermato-Venereologica</i> , 2010, 90, 461-467.	1.3	24
194	Antimicrobial susceptibility and genetic characteristics of <i>Neisseria gonorrhoeae</i> isolates from India, Pakistan and Bhutan in 2007-2011. <i>BMC Infectious Diseases</i> , 2013, 13, 35.	2.9	24
195	Genomic Characterization of Urethritis-Associated <i>Neisseria meningitidis</i> Shows that a Wide Range of <i>N. meningitidis</i> Strains Can Cause Urethritis. <i>Journal of Clinical Microbiology</i> , 2017, 55, 3374-3383.	3.9	24
196	In vitro antimicrobial combination testing of and evolution of resistance to the first-in-class spiroprimidinetriene zoliflodacin combined with six therapeutically relevant antimicrobials for <i>Neisseria gonorrhoeae</i> . <i>Journal of Antimicrobial Chemotherapy</i> , 2019, 74, 3521-3529.	3.0	24
197	Antimicrobial susceptibility of <i>Neisseria gonorrhoeae</i> isolates and treatment of gonorrhoea patients in Ternopil and Dnipropetrovsk regions of Ukraine, 2013-2018. <i>Apmis</i> , 2019, 127, 503-509.	2.0	24
198	Background review for the 2020 European guideline for the diagnosis and treatment of gonorrhoea in adults. <i>International Journal of STD and AIDS</i> , 2021, 32, 108-126.	1.1	24

#	ARTICLE	IF	CITATIONS
199	The <i>porA</i> pseudogene of <i>Neisseria gonorrhoeae</i> - low level of genetic polymorphism and a few, mainly identical, inactivating mutations. <i>Apmis</i> , 2005, 113, 410-419.	2.0	23
200	Detection of <i>gyrA</i> mutations associated with ciprofloxacin resistance in <i>Neisseria gonorrhoeae</i> by rapid and reliable pre-programmed short DNA sequencing. <i>International Journal of Antimicrobial Agents</i> , 2005, 26, 486-490.	2.5	23
201	Simultaneous species identification and detection of rifampicin resistance in staphylococci by sequencing of the <i>rpoB</i> gene. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 2009, 28, 183-190.	2.9	23
202	Prevalence trends in Sweden for the new variant of <i>Chlamydia trachomatis</i> . <i>Clinical Microbiology and Infection</i> , 2011, 17, 683-689.	6.0	23
203	Successful Combination of Nucleic Acid Amplification Test Diagnostics and Targeted Deferred <i>Neisseria gonorrhoeae</i> Culture. <i>Journal of Clinical Microbiology</i> , 2015, 53, 1884-1890.	3.9	23
204	Background review for the ~2015 European guideline on the management of <i>Chlamydia trachomatis</i> infections™. <i>International Journal of STD and AIDS</i> , 2015, , 095646241561883.	1.1	23
205	Syphilis epidemiology in 1994~2013, molecular epidemiological strain typing and determination of macrolide resistance in <i>Treponema pallidum</i> in 2013~2014 in Tuva Republic, Russia. <i>Apmis</i> , 2016, 124, 595-602.	2.0	23
206	Pharmacodynamic Evaluation of Dosing, Bacterial Kill, and Resistance Suppression for Zoliflodacin Against <i>Neisseria gonorrhoeae</i> in a Dynamic Hollow Fiber Infection Model. <i>Frontiers in Pharmacology</i> , 2021, 12, 682135.	3.5	23
207	C4BP-IgM protein as a therapeutic approach to treat <i>Neisseria gonorrhoeae</i> infections. <i>JCI Insight</i> , 2019, 4, .	5.0	23
208	Laboratory diagnosis of <i>Neisseria gonorrhoeae</i> in St Petersburg, Russia: inventory, performance characteristics and recommended optimisations. <i>Sexually Transmitted Infections</i> , 2006, 82, 41-44.	1.9	22
209	<i>Propionibacterium acnes</i> as an etiological agent of arthroplastic and osteosynthetic infections ~ Two cases with specific clinical presentation including formation of draining fistulae. <i>Anaerobe</i> , 2010, 16, 304-306.	2.1	22
210	Resistance to Azithromycin of <i>Neisseria gonorrhoeae</i> Isolates From 2 Cities in China. <i>Sexually Transmitted Diseases</i> , 2011, 38, 764-768.	1.7	22
211	High prevalence of <i>Chlamydia trachomatis</i> , <i>Neisseria gonorrhoeae</i> and particularly <i>Trichomonas vaginalis</i> diagnosed using US FDA~approved Aptima molecular tests and evaluation of conventional routine diagnostic tests in Ternopil, Ukraine. <i>Apmis</i> , 2019, 127, 627-634.	2.0	22
212	<i>Neisseria gonorrhoeae</i> Sequence Typing for Antimicrobial Resistance (NG-STAR) clonal complexes are consistent with genomic phylogeny and provide simple nomenclature, rapid visualization and antimicrobial resistance (AMR) lineage predictions. <i>Journal of Antimicrobial Chemotherapy</i> , 2021, 76, 940-944.	3.0	22
213	Clinical Validation of a Real-Time Polymerase Chain Reaction Detection of <i>Neisseria gonorrhoeae porA</i> Pseudogene Versus Culture Techniques. <i>Sexually Transmitted Diseases</i> , 2008, 35, 517-520.	1.7	21
214	First evaluation of polymerase chain reaction assays used for diagnosis of <i>Mycoplasma genitalium</i> in Russia. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2009, 23, 1164-1172.	2.4	21
215	Time to clearance of <i>Chlamydia trachomatis</i> RNA and DNA after treatment in patients coinfecting with <i>Neisseria gonorrhoeae</i> ~ a prospective cohort study. <i>BMC Infectious Diseases</i> , 2016, 16, 554.	2.9	21
216	Developing target product profiles for <i>Neisseria gonorrhoeae</i> diagnostics in the context of antimicrobial resistance: An expert consensus. <i>PLoS ONE</i> , 2020, 15, e0237424.	2.5	21

#	ARTICLE	IF	CITATIONS
217	Genosubtyping by sequencing group A, B and C meningococci; a tool for epidemiological studies of epidemics, clusters and sporadic cases. <i>Apmis</i> , 2000, 108, 509-516.	2.0	21
218	The Russian gonococcal antimicrobial susceptibility programme (RU-GASP)–national resistance prevalence in 2007 and 2008, and trends during 2005-2008. <i>Eurosurveillance</i> , 2010, 15, .	7.0	21
219	Guidelines for the laboratory diagnosis of <i>Chlamydia trachomatis</i> infections in East European countries. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2009, 23, 1353-1363.	2.4	20
220	Antibiotic susceptibility in prostate-derived <i>Propionibacterium acnes</i> isolates. <i>Apmis</i> , 2012, 120, 778-785.	2.0	20
221	Prevalence and Molecular Epidemiological Typing of Penicillinase-Producing <i>Neisseria gonorrhoeae</i> and Their blaTEM-135 Gene Variants in Nanjing, China. <i>Sexually Transmitted Diseases</i> , 2013, 40, 872-876.	1.7	20
222	Macrolide and fluoroquinolone resistance in <i>Mycoplasma genitalium</i> in two Swedish counties, 2011–2015. <i>Apmis</i> , 2018, 126, 123-127.	2.0	20
223	Ten years transmission of the new variant of <i>Chlamydia trachomatis</i> in Sweden: prevalence of infections and associated complications. <i>Sexually Transmitted Infections</i> , 2018, 94, 100-104.	1.9	20
224	Establishment of a Gonococcal Antimicrobial Surveillance Programme, in Accordance With World Health Organization Standards, in CÔte d'Ivoire, Western Africa, 2014–2017. <i>Sexually Transmitted Diseases</i> , 2019, 46, 179-184.	1.7	20
225	Mutations in penicillin-binding protein 2 from cephalosporin-resistant <i>Neisseria gonorrhoeae</i> hinder ceftriaxone acylation by restricting protein dynamics. <i>Journal of Biological Chemistry</i> , 2020, 295, 7529-7543.	3.4	20
226	Molecular epidemiology of <i>Neisseria gonorrhoeae</i> - identification of the first presumed Swedish transmission chain of an azithromycin-resistant strain. <i>Apmis</i> , 2006, 114, 67-71.	2.0	19
227	Mutations in fusA Associated with Posttherapy Fusidic Acid Resistance in <i>Clostridium difficile</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2007, 51, 1840-1843.	3.2	19
228	Evaluation of six nucleic acid amplification tests used for diagnosis of <i>Neisseria gonorrhoeae</i> in Russia compared with an international strictly validated real-time <i>porA</i> pseudogene polymerase chain reaction. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2009, 23, 1246-1253.	2.4	19
229	High in vitro activity of a novel dual bacterial topoisomerase inhibitor of the ATPase activities of GyrB and ParE (VT12-008911) against <i>Neisseria gonorrhoeae</i> isolates with various high-level antimicrobial resistance and multidrug resistance. <i>Journal of Antimicrobial Chemotherapy</i> , 2014, 69, 1866-1872.	3.0	19
230	Five-day Azithromycin Treatment Regimen for <i>Mycoplasma genitalium</i> Infection Also Effectively Eradicates <i>Chlamydia trachomatis</i> . <i>Acta Dermato-Venereologica</i> , 2015, 95, 730-732.	1.3	19
231	Pulsed-Field Gel Electrophoresis as an Epidemiologic Tool for <i>Neisseria gonorrhoeae</i> . <i>Sexually Transmitted Diseases</i> , 2002, 29, 25-31.	1.7	18
232	Laboratory diagnostics for non-viral sexually transmitted infections in St. Petersburg, Russia: current situation and hallmarks for improvements. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2008, 22, 1094-1100.	2.4	18
233	Phenotypic and genotypic properties of <i>Neisseria gonorrhoeae</i> isolates in Norway in 2009: antimicrobial resistance warrants an immediate change in national management guidelines. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 2012, 31, 1181-1186.	2.9	18
234	Antimicrobial susceptibility/resistance and genetic characteristics of <i>Neisseria gonorrhoeae</i> isolates from Poland, 2010-2012. <i>BMC Infectious Diseases</i> , 2014, 14, 65.	2.9	18

#	ARTICLE	IF	CITATIONS
235	Antimicrobial susceptibility in <i>Neisseria gonorrhoeae</i> isolates from five sentinel surveillance sites in Zimbabwe, 2015–2016. <i>Sexually Transmitted Infections</i> , 2018, 94, 62-66.	1.9	18
236	The Finnish New Variant of <i>Chlamydia trachomatis</i> with a Single Nucleotide Polymorphism in the 23S rRNA Target Escapes Detection by the Aptima Combo 2 Test. <i>Microorganisms</i> , 2019, 7, 227.	3.6	18
237	Antimicrobial resistance (AMR) and molecular characterization of <i>Neisseria gonorrhoeae</i> in Ghana, 2012-2015. <i>PLoS ONE</i> , 2019, 14, e0223598.	2.5	18
238	Antimicrobial resistance prediction in <i>Neisseria gonorrhoeae</i> : current status and future prospects. <i>Expert Review of Molecular Diagnostics</i> , 2022, 22, 29-48.	3.1	18
239	Genetic homogeneity/heterogeneity of <i>Propionibacterium acnes</i> isolated from patients during cardiothoracic reoperation. <i>Anaerobe</i> , 2007, 13, 121-126.	2.1	17
240	Appropriate Time for Test-of-Cure when Diagnosing Gonorrhoea with a Nucleic Acid Amplification Test. <i>Acta Dermato-Venereologica</i> , 2012, 92, 316-319.	1.3	17
241	Analytical Specificity and Sensitivity of the APTIMA Combo 2 and APTIMA GC Assays for Detection of Commensal <i>Neisseria</i> Species and <i>Neisseria gonorrhoeae</i> on the Gen-Probe Panther Instrument. <i>Sexually Transmitted Diseases</i> , 2013, 40, 175-178.	1.7	17
242	Analytical evaluation of nine serological assays for diagnosis of syphilis. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2015, 29, 2369-2376.	2.4	17
243	In vitro activities of the novel bicyclics modithromycin (EDP-420, EP-013420, S-013420) and EDP-322 against MDR clinical <i>Neisseria gonorrhoeae</i> isolates and international reference strains. <i>Journal of Antimicrobial Chemotherapy</i> , 2015, 70, 173-177.	3.0	17
244	Gentamicin in vitro activity and tentative gentamicin interpretation criteria for the CLSI and calibrated dichotomous sensitivity disc diffusion methods for <i>Neisseria gonorrhoeae</i> . <i>Journal of Antimicrobial Chemotherapy</i> , 2016, 71, 1856-1859.	3.0	17
245	Emergence and Spread of Cephalosporin-Resistant <i>Neisseria gonorrhoeae</i> with Mosaic <i>penA</i> Alleles, South Korea, 2012–2017. <i>Emerging Infectious Diseases</i> , 2019, 25, 416-424.	4.3	17
246	Prevalence, Macrolide Resistance, and Fluoroquinolone Resistance in <i>Mycoplasma genitalium</i> in Men Who Have Sex With Men Attending an Sexually Transmitted Disease Clinic in Dublin, Ireland in 2017–2018. <i>Sexually Transmitted Diseases</i> , 2019, 46, e35-e37.	1.7	17
247	Antimicrobial resistance in <i>Mycoplasma genitalium</i> sampled from the British general population. <i>Sexually Transmitted Infections</i> , 2020, 96, 464-468.	1.9	17
248	Recent trends in gonorrhoea and syphilis epidemiology in Sweden: 2007 to 2011. <i>Eurosurveillance</i> , 2012, 17, .	7.0	17
249	The European gonococcal antimicrobial surveillance programme, 2009. <i>Eurosurveillance</i> , 2011, 16, .	7.0	17
250	Antibiotic susceptibility of <i>Neisseria gonorrhoeae</i> in Arkhangelsk, Russia. <i>Sexually Transmitted Infections</i> , 2007, 83, 133-135.	1.9	16
251	The <i>Neisseria gonorrhoeae</i> population in Sweden during 2005–phenotypes, genotypes and antibiotic resistance. <i>Apmis</i> , 2008, 116, 181-189.	2.0	16
252	Population-based assessment of <i>Mycoplasma genitalium</i> in Vietnam – low prevalence among married women of reproductive age in a rural area. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2009, 23, 533-537.	2.4	16

#	ARTICLE	IF	CITATIONS
253	Genetic diversity of <i>bla</i> TEM alleles, antimicrobial susceptibility and molecular epidemiological characteristics of penicillinase-producing <i>Neisseria gonorrhoeae</i> from England and Wales. <i>Journal of Antimicrobial Chemotherapy</i> , 2015, 70, dkv260.	3.0	16
254	<i>In vitro</i> activity and time-kill curve analysis of sitafloxacin against a global panel of antimicrobial-resistant and multidrug-resistant <i>Neisseria gonorrhoeae</i> isolates. <i>Apmis</i> , 2018, 126, 29-37.	2.0	16
255	Pathogenic Interplay Between <i>Chlamydia trachomatis</i> and <i>Neisseria gonorrhoeae</i> that Influences Management and Control Efforts—More Questions than Answers?. <i>Current Clinical Microbiology Reports</i> , 2019, 6, 182-191.	3.4	16
256	Pharmacokinetic/pharmacodynamic considerations for new and current therapeutic drugs for uncomplicated gonorrhoea—challenges and opportunities. <i>Clinical Microbiology and Infection</i> , 2020, 26, 1630-1635.	6.0	16
257	Can the Swedish new variant of <i>Chlamydia trachomatis</i> (nvCT) be detected by UK NEQAS participants from seventeen European countries and five additional countries/regions in 2009?. <i>Eurosurveillance</i> , 2009, 14, .	7.0	16
258	Staphylococcal cassette chromosome mec (SCCmec) and arginine catabolic mobile element (ACME) in <i>Staphylococcus epidermidis</i> isolated from prosthetic joint infections. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 2013, 32, 691-697.	2.9	15
259	Evaluation and subsequent optimizations of the quantitative AmpliSens Florocenosis/Bacterial vaginosis—FRT multiplex real-time PCR assay for diagnosis of bacterial vaginosis. <i>Apmis</i> , 2016, 124, 1099-1108.	2.0	15
260	Performance characteristics of newer MIC gradient strip tests compared with the Etest for antimicrobial susceptibility testing of <i>Neisseria gonorrhoeae</i> . <i>Apmis</i> , 2018, 126, 822-827.	2.0	15
261	Implementation of a standardised and quality-assured enhanced gonococcal antimicrobial surveillance programme in accordance with WHO protocols in Kampala, Uganda. <i>Sexually Transmitted Infections</i> , 2021, 97, 312-316.	1.9	15
262	Finnish new variant of <i>Chlamydia trachomatis</i> escaping detection in the Aptima Combo 2 assay also present in Årbro County, Sweden, May 2019. <i>Eurosurveillance</i> , 2019, 24, .	7.0	15
263	Intimate physical contact between people from different households during the COVID-19 pandemic: a mixed-methods study from a large, quasi-representative survey (Natsal-COVID). <i>BMJ Open</i> , 2022, 12, e055284.	1.9	15
264	Pharmacodynamic Evaluation of Zoliflodacin Treatment of <i>Neisseria gonorrhoeae</i> Strains With Amino Acid Substitutions in the Zoliflodacin Target GyrB Using a Dynamic Hollow Fiber Infection Model. <i>Frontiers in Pharmacology</i> , 2022, 13, 874176.	3.5	15
265	Comparison of microscopy, culture and in-house PCR and NASBA assays for diagnosis of <i>Neisseria gonorrhoeae</i> in Russia. <i>Apmis</i> , 2008, 116, 133-138.	2.0	14
266	Evaluation of the new COBAS TaqMan CT test v2.0 and impact on the proportion of new variant <i>Chlamydia trachomatis</i> by the introduction of diagnostics detecting new variant C <i>trachomatis</i> in Örebro county, Sweden. <i>Sexually Transmitted Infections</i> , 2009, 85, 190-193.	1.9	14
267	Gonorrhoea surveillance, laboratory diagnosis and antimicrobial susceptibility testing of <i>Neisseria gonorrhoeae</i> in 11 countries of the eastern part of the WHO European region. <i>Apmis</i> , 2011, 119, 643-649.	2.0	14
268	Multilocus sequence typing and repetitive-sequence-based PCR (DiversiLab) for molecular epidemiological characterization of <i>Propionibacterium acnes</i> isolates of heterogeneous origin. <i>Anaerobe</i> , 2012, 18, 392-399.	2.1	14
269	Verified clinical failure with cefotaxime 1g for treatment of gonorrhoea in the Netherlands: a case report. <i>Sexually Transmitted Infections</i> , 2014, 90, 513-514.	1.9	14
270	Prospects of untreatable gonorrhoea and ways forward. <i>Future Microbiology</i> , 2015, 10, 313-316.	2.0	14



#	ARTICLE	IF	CITATIONS
271	Proof of principle for effectiveness of a gonorrhoea vaccine. <i>Nature Reviews Urology</i> , 2017, 14, 643-644.	3.8	14
272	Genetic variation regulates the activation and specificity of Restriction-Modification systems in <i>Neisseria gonorrhoeae</i> . <i>Scientific Reports</i> , 2019, 9, 14685.	3.3	14
273	Ten years of external quality assessment (EQA) of <i>Neisseria gonorrhoeae</i> antimicrobial susceptibility testing in Europe elucidate high reliability of data. <i>BMC Infectious Diseases</i> , 2019, 19, 281.	2.9	14
274	Adherence to the 2012 European gonorrhoea guideline in the WHO European Region according to the 2018-19 International Union against Sexually Transmitted Infections European Collaborative Clinical Group gonorrhoea survey. <i>International Journal of STD and AIDS</i> , 2020, 31, 69-76.	1.1	14
275	In vitro activity of the first-in-class triazaacenaphthylene gepotidacin alone and in combination with doxycycline against drug-resistant and -susceptible <i>Mycoplasma genitalium</i> . <i>Emerging Microbes and Infections</i> , 2020, 9, 1388-1392.	6.5	14
276	Clinical <i>Neisseria gonorrhoeae</i> isolate with a <i>N. meningitidis</i> <i>porA</i> gene and no prolyliminopeptidase activity, Sweden, 2011 – danger of false-negative genetic and culture diagnostic results. <i>Eurosurveillance</i> , 2012, 17, .	7.0	14
277	Laboratory Diagnosis of Sexually Transmitted Infections in Estonia in 2001-2002: Shortcomings With Impact on Diagnostic Quality and Surveillance. <i>Sexually Transmitted Diseases</i> , 2005, 32, 759-764.	1.7	13
278	Real-time PCR and subsequent pyrosequencing for screening of <i>penA</i> mosaic alleles and prediction of reduced susceptibility to expanded-spectrum cephalosporins in <i>Neisseria gonorrhoeae</i> . <i>Apmis</i> , 2008, 116, 1004-1008.	2.0	13
279	Quality enhancements and quality assurance of laboratory diagnosis of sexually transmitted infections in Eastern Europe. <i>International Journal of STD and AIDS</i> , 2009, 20, 365-367.	1.1	13
280	Phenotypic and genetic characterisation of bacterial sexually transmitted infections in Bissau, Guinea-Bissau, West Africa: a prospective cohort study. <i>BMJ Open</i> , 2012, 2, e000636.	1.9	13
281	Future treatment of gonorrhoea – novel emerging drugs are essential and in progress?. <i>Expert Opinion on Emerging Drugs</i> , 2015, 20, 357-360.	2.4	13
282	In vitro activity of the novel oral antimicrobial SMT-571, with a new mechanism of action, against MDR and XDR <i>Neisseria gonorrhoeae</i> : future treatment option for gonorrhoea?. <i>Journal of Antimicrobial Chemotherapy</i> , 2019, 74, 1591-1594.	3.0	13
283	Genomic epidemiology and antimicrobial resistance determinants of <i>Neisseria gonorrhoeae</i> isolates from Ukraine, 2013-2018. <i>Apmis</i> , 2020, 128, 465-475.	2.0	13
284	Letter to the editor: <i>Chlamydia trachomatis</i> samples testing falsely negative in the Aptima Combo 2 test in Finland, 2019. <i>Eurosurveillance</i> , 2019, 24, .	7.0	13
285	In Vitro Activity of Sitafloxacin and Additional Newer Generation Fluoroquinolones Against Ciprofloxacin-Resistant <i>Neisseria gonorrhoeae</i> Isolates. <i>Microbial Drug Resistance</i> , 2018, 24, 30-34.	2.0	12
286	Aptima <i>Trichomonas vaginalis</i> assay elucidates significant underdiagnosis of trichomoniasis among women in Brazil according to an observational study. <i>Sexually Transmitted Infections</i> , 2019, 95, 129-132.	1.9	12
287	Associations between antimicrobial susceptibility/resistance of <i>Neisseria gonorrhoeae</i> isolates in European Union/European Economic Area and patients' gender, sexual orientation and anatomical site of infection, 2009-2016. <i>BMC Infectious Diseases</i> , 2021, 21, 273.	2.9	12
288	Phenotypic and genotypic characterization of prolyliminopeptidase-negative <i>Neisseria gonorrhoeae</i> isolates in Denmark. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 2005, 24, 280-283.	2.9	11

#	ARTICLE	IF	CITATIONS
289	Diagnosis of Chlamydia trachomatis in Russia ? in-house PCR assays may be effective but overall optimization and quality assurance are urgently needed. <i>Apmis</i> , 2006, 114, 500-507.	2.0	11
290	Evaluation of polymerase chain reaction assays for the diagnosis of <i>Trichomonas vaginalis</i> infection in Russia. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2013, 27, e217-23.	2.4	11
291	Antimicrobial susceptibility testing of <i>Neisseria gonorrhoeae</i> isolates in Pakistan by Etest compared to Calibrated Dichotomous Sensitivity and Clinical Laboratory Standards Institute disc diffusion techniques. <i>BMC Microbiology</i> , 2016, 16, 236.	3.3	11
292	High In Vitro Susceptibility to the First-in-Class Spiropyrimidinetrione Zoliflodacin among Consecutive Clinical <i>Neisseria gonorrhoeae</i> Isolates from Thailand and South Africa. <i>Antimicrobial Agents and Chemotherapy</i> , 2019, 63, .	3.2	11
293	The first wide-scale drug repurposing screen using the Prestwick Chemical Library (1200 bioactive) Tj ETQq1 1 0.784314 rgBT /Over and many additional drugs. <i>Apmis</i> , 2020, 128, 242-250.	2.0	11
294	Genomic surveillance and antimicrobial resistance in <i>Neisseria gonorrhoeae</i> isolates in Bangkok, Thailand in 2018. <i>Journal of Antimicrobial Chemotherapy</i> , 2022, , .	3.0	11
295	Home sampling and pooling of vaginal samples are effective tools for genetic screening of <i>Chlamydia trachomatis</i> among high school female students in Lithuania. <i>Scandinavian Journal of Infectious Diseases</i> , 2008, 40, 88-93.	1.5	10
296	Distribution of <i>Chlamydia trachomatis</i> ompA genovars and the new variant of <i>C. trachomatis</i> in the Gästeborg area, Sweden. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 2010, 29, 609-611.	2.9	10
297	The new variant of <i>Chlamydia trachomatis</i> was present as early as 2003 in Årebro County, Sweden, but remained undetected until 2006. <i>Sexually Transmitted Infections</i> , 2013, 89, 607-608.	1.9	10
298	Antimicrobial resistance and <i>Neisseria gonorrhoeae</i> multiantigen sequence typing (NG-MAST) genotypes in <i>N. gonorrhoeae</i> during 2012–2014 in Karachi, Pakistan. <i>BMC Infectious Diseases</i> , 2016, 16, 353.	2.9	10
299	Efflux Pumps in <i>Neisseria gonorrhoeae</i> : Contributions to Antimicrobial Resistance and Virulence. , 2016, , 439-469.		10
300	Antibiotic resistance and NG-MAST sequence types of <i>Neisseria gonorrhoeae</i> isolates in Poland compared to the world. <i>Postepy Dermatologii i Alergologii</i> , 2018, 35, 546-551.	0.9	10
301	Gonorrhoea treatment combined with population-level general cephalosporin and quinolone consumption may select for <i>Neisseria gonorrhoeae</i> antimicrobial resistance at the levels of NG-MAST genogroup: An ecological study in Europe. <i>Journal of Global Antimicrobial Resistance</i> , 2020, 23, 377-384.	2.2	10
302	Sensitivity, specificity, inclusivity and exclusivity of the updated Aptima Combo 2 assay, which provides detection coverage of the new diagnostic-escape <i>Chlamydia trachomatis</i> variants. <i>BMC Infectious Diseases</i> , 2020, 20, 419.	2.9	10
303	Evaluation of the SpeedxResistancePlus®GC and Speedx GC 23S 2611 (beta) molecular assays for prediction of antimicrobial resistance/susceptibility to ciprofloxacin and azithromycin in <i>Neisseria gonorrhoeae</i> . <i>Journal of Antimicrobial Chemotherapy</i> , 2021, 76, 84-90.	3.0	10
304	The Finnish new variant of <i>Chlamydia trachomatis</i> ™ escaping detection in the Aptima Combo 2 assay is widespread across Norway, June to August 2019. <i>Eurosurveillance</i> , 2019, 24, .	7.0	10
305	The Swedish new variant of <i>Chlamydia trachomatis</i> (nvCT) remains undetected by many European laboratories as revealed in the recent PCR/NAT ring trial organised by INSTAND e.V., Germany. <i>Eurosurveillance</i> , 2009, 14, .	7.0	10
306	Transformation of ciprofloxacin-resistant <i>Neisseria gonorrhoeae</i> gyrA, parE and porB1b genes. <i>International Journal of Antimicrobial Agents</i> , 2006, 28, 206-211.	2.5	9

#	ARTICLE	IF	CITATIONS
307	Antimicrobial susceptibility/resistance and molecular epidemiological characteristics of <i>Neisseria gonorrhoeae</i> in 2009 in Belarus. <i>Apmis</i> , 2011, 119, 537-542.	2.0	9
308	Evaluation of <i>Neisseria gonorrhoeae</i> Multiple-Locus Variable-Number Tandem-Repeat Analysis, <i>N. gonorrhoeae</i> Multiantigen Sequence Typing, and Full-Length <i>porB</i> Gene Sequence Analysis for Molecular Epidemiological Typing. <i>Journal of Clinical Microbiology</i> , 2012, 50, 180-183.	3.9	9
309	Phylogenomics for drug-resistant <i>Neisseria gonorrhoeae</i> . <i>Lancet Infectious Diseases</i> , The, 2014, 14, 179-180.	9.1	9
310	<i>Trichomonas vaginalis</i> Infections are Rare Among Young Patients Attending an STI Clinic in Sweden. <i>Acta Dermato-Venereologica</i> , 2015, 95, 343-344.	1.3	9
311	Prevalence and risk factors associated with <i>Chlamydia trachomatis</i> , <i>Neisseria gonorrhoeae</i> , and <i>Mycoplasma genitalium</i> among women in Pelotas, Southern Brazil. <i>International Journal of STD and AIDS</i> , 2020, 31, 432-439.	1.1	9
312	Accurate, rapid, point-of-care tests for sexually transmitted infections. <i>Lancet Infectious Diseases</i> , The, 2021, 21, 584-586.	9.1	9
313	Genomic and phenotypic characterisation of invasive neonatal and colonising group B <i>Streptococcus</i> isolates from Slovenia, 2001–2018. <i>BMC Infectious Diseases</i> , 2020, 20, 958.	2.9	9
314	Diagnosis of non-viral sexually transmitted infections in Lithuania and international recommendations. <i>Eurosurveillance</i> , 2006, 11, 9-10.	7.0	9
315	Potential impact of the COVID-19 pandemic on the national and regional incidence, epidemiology and diagnostic testing of chlamydia and gonorrhoea in Sweden, 2020. <i>Apmis</i> , 2022, 130, 34-42.	2.0	9
316	Gentamicin Susceptibility in <i>Neisseria gonorrhoeae</i> and Treatment Outcomes for Urogenital Gonorrhoea After 25 Years of Sustained Gentamicin Use in Malawi. <i>Sexually Transmitted Diseases</i> , 2022, 49, 251-256.	1.7	9
317	Clinical Importance of Superior Sensitivity of the Aptima TMA-Based Assays for <i>Mycoplasma genitalium</i> Detection. <i>Journal of Clinical Microbiology</i> , 2022, 60, e0236921.	3.9	9
318	First Reported Case of the Swedish New Variant of <i>Chlamydia trachomatis</i> (nvCT) in Eastern Europe (Russia), and Evaluation of Russian Nucleic Acid Amplification Tests Regarding Their Ability to Detect nvCT. <i>Acta Dermato-Venereologica</i> , 2012, 92, 330-331.	1.3	8
319	Mitigating the Emergence and Spread of Multidrug- and Extensively Drug-Resistant Gonorrhoea. <i>Sexually Transmitted Diseases</i> , 2014, 41, 238-239.	1.7	8
320	Prediction of Minimum Inhibitory Concentrations of Antimicrobials for <i>Neisseria gonorrhoeae</i> Using Whole-Genome Sequencing. <i>Methods in Molecular Biology</i> , 2019, 1997, 59-76.	0.9	8
321	The 2018–19 International Union against Sexually Transmitted Infections European Collaborative Clinical Group report on the diagnosis and treatment of gonorrhoea in Europe. <i>International Journal of STD and AIDS</i> , 2020, 31, 77-81.	1.1	8
322	Prevalence of <i>Mycoplasma genitalium</i> and Antibiotic Resistance-Associated Mutations in Patients at a Sexually Transmitted Infection Clinic in Iceland, and Comparison of the S-DiaMGTV and Aptima <i>Mycoplasma genitalium</i> Assays for Diagnosis. <i>Journal of Clinical Microbiology</i> , 2020, 58, .	3.9	8
323	Antimicrobial resistance in <i>Neisseria gonorrhoeae</i> isolates and gonorrhoea treatment in the Republic of Belarus, Eastern Europe, 2009–2019. <i>BMC Infectious Diseases</i> , 2021, 21, 520.	2.9	8
324	First National Genomic Epidemiological Study of <i>Neisseria gonorrhoeae</i> Strains Spreading Across Sweden in 2016. <i>Frontiers in Microbiology</i> , 2021, 12, 820998.	3.5	8

#	ARTICLE	IF	CITATIONS
325	The European response to control and manage multi- and extensively drug-resistant <i>Neisseria gonorrhoeae</i> . <i>Eurosurveillance</i> , 2022, 27, .	7.0	8
326	Changes in testing and incidence of <i>Chlamydia trachomatis</i> and <i>Neisseria gonorrhoeae</i> – the possible impact of the COVID-19 pandemic in the three Scandinavian countries. <i>Infectious Diseases</i> , 2022, 54, 623-631.	2.8	8
327	Genotypic and Phenotypic Stability of <i>Helicobacter pylori</i> Markers in a Nine-Year Follow-up Study of Patients with Noneradicated Infection. <i>Digestive Diseases and Sciences</i> , 2005, 50, 375-380.	2.3	7
328	Combined Real-Time PCR and Pyrosequencing Strategy for Objective, Sensitive, Specific, and High-Throughput Identification of Reduced Susceptibility to Penicillins in <i>Neisseria meningitidis</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2008, 52, 753-756.	3.2	7
329	Sexual behaviours, knowledge and attitudes regarding safe sex, and prevalence of non-viral sexually transmitted infections among attendees of youth clinics in St. Petersburg, Russia. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2013, 27, e75-84.	2.4	7
330	Evaluation of the New BD Max GC Real-Time PCR Assay, Analytically and Clinically as a Supplementary Test for the BD ProbeTec GC Qx Amplified DNA Assay, for Molecular Detection of <i>Neisseria gonorrhoeae</i> . <i>Journal of Clinical Microbiology</i> , 2015, 53, 3935-3937.	3.9	7
331	Role of Molecular Biology in Diagnosis and Characterization of Vulvo-Vaginitis in Clinical Practice. <i>Gynecologic and Obstetric Investigation</i> , 2017, 82, 607-616.	1.6	7
332	Antimicrobial resistance in <i>Neisseria gonorrhoeae</i> isolates from foreign-born population in the European Gonococcal Antimicrobial Surveillance Programme. <i>Sexually Transmitted Infections</i> , 2020, 96, 204-210.	1.9	7
333	A profile of the FDA-approved and CE/IVD-marked Aptima <i>Mycoplasma genitalium</i> assay (Hologic) and key priorities in the management of <i>M. genitalium</i> infections. <i>Expert Review of Molecular Diagnostics</i> , 2020, 20, 1063-1074.	3.1	7
334	Genomic Epidemiology of Azithromycin-Nonsusceptible <i>Neisseria gonorrhoeae</i> , Argentina, 2005–2019. <i>Emerging Infectious Diseases</i> , 2021, 27, 2369-2378.	4.3	7
335	Emergence of the new variant of <i>Chlamydia trachomatis</i> in a defined area of Sweden before 2002?. <i>Sexually Transmitted Infections</i> , 2010, 86, 337-341.	1.9	6
336	Does the 2012 IUSTI ECCG report on the diagnosis and management of <i>Neisseria gonorrhoeae</i> infections in Europe™ depict the situation in Europe?. <i>International Journal of STD and AIDS</i> , 2013, 24, 423-426.	1.1	6
337	First antimicrobial resistance data and genetic characteristics of <i>Neisseria gonorrhoeae</i> isolates from Estonia, 2009–2013. <i>New Microbes and New Infections</i> , 2014, 2, 150-153.	1.6	6
338	Protection against genital tract <i>Chlamydia trachomatis</i> infection following intranasal immunization with a novel recombinant MOMP VS <sub>2/4</sub> antigen. <i>Apmis</i> , 2016, 124, 1078-1086.	2.0	6
339	<i>Trichomonas vaginalis</i> is very rare among women with vaginal discharge in Podlaskie province, Poland. <i>Apmis</i> , 2017, 125, 840-843.	2.0	6
340	Rise and fall of the new variant of <i>Chlamydia trachomatis</i> in Sweden: mathematical modelling study. <i>Sexually Transmitted Infections</i> , 2020, 96, 375-379.	1.9	6
341	Most but not all laboratories can detect the recently emerged <i>Neisseria gonorrhoeae</i> porA mutants – results from the QCMD 2013 <i>N. gonorrhoeae</i> external quality assessment programme. <i>Eurosurveillance</i> , 2014, 19, 20711.	7.0	6
342	Clinical <i>Neisseria gonorrhoeae</i> isolate with a <i>N. meningitidis</i> porA gene and no prolyliminopeptidase activity, Sweden, 2011: danger of false-negative genetic and culture diagnostic results. <i>Eurosurveillance</i> , 2012, 17, .	7.0	6

#	ARTICLE	IF	CITATIONS
343	National surveillance of <i>Neisseria gonorrhoeae</i> antimicrobial susceptibility and epidemiological data of gonorrhoea patients across Brazil, 2018–20. JAC-Antimicrobial Resistance, 2022, 4, .	2.1	6
344	The evolution of infectious agents in relation to sex in animals and humans: brief discussions of some individual organisms. Annals of the New York Academy of Sciences, 2011, 1230, 74-107.	3.8	5
345	Challenges with antimicrobial susceptibility testing for <i>Neisseria gonorrhoeae</i> in the era of extensively drug-resistant gonorrhoea – molecular antimicrobial resistance testing crucial. Pathogens and Global Health, 2014, 108, 214-215.	2.3	5
346	Antimicrobial Resistance Expressed by <i>Neisseria gonorrhoeae</i> : A Major Global Public Health Problem in the 21st Century. , 2016, , 213-237.		5
347	Fitness cost and benefit of antimicrobial resistance in <i>Neisseria gonorrhoeae</i> : Multidisciplinary approaches are needed. PLoS Medicine, 2017, 14, e1002423.	8.4	5
348	<i>Trichomonas vaginalis</i> is Rare Among Women in Iceland. Acta Dermato-Venereologica, 2017, 97, 1258-1260.	1.3	5
349	Antimicrobial Susceptibility of <i>Neisseria gonorrhoeae</i> Isolates in Yaoundé, Cameroon From 2009 to 2014. Sexually Transmitted Diseases, 2018, 45, e101-e103.	1.7	5
350	A <i>Chlamydia trachomatis</i> 23S rRNA G1523A variant escaping detection in the Aptima Combo 2 assay (Hologic) was widespread across Denmark in July–September 2019. Apmis, 2020, 128, 440-444.	2.0	5
351	First characterisation of antimicrobial susceptibility and resistance of <i>Neisseria gonorrhoeae</i> isolates in Qatar, 2017–2020. PLoS ONE, 2022, 17, e0264737.	2.5	5
352	Cefpodoxime 10 mg disc screening test for detection of <i>Neisseria gonorrhoeae</i> with mosaic PBP2 and decreased susceptibility to extended-spectrum cephalosporins for public health purposes. Apmis, 2011, 119, 356-363.	2.0	4
353	Antimicrobial resistance and molecular epidemiological typing of <i>Neisseria gonorrhoeae</i> isolates from Kyrgyzstan in Central Asia, 2012 and 2017. BMC Infectious Diseases, 2021, 21, 559.	2.9	4
354	Molecular epidemiological typing of <i>Neisseria gonorrhoeae</i> isolates identifies a novel association between genogroup G10557 (G7072) and decreased susceptibility to cefixime, Germany, 2014 to 2017. Eurosurveillance, 2020, 25, .	7.0	4
355	Lymphogranuloma venereum (LGV) in men who have sex with men (MSM): a re-emerging problem, Malta, 2018. Eurosurveillance, 2018, 23, .	7.0	4
356	Gonococcal Clinical Strains Bearing a Common <i>gdhR</i> Single Nucleotide Polymorphism That Results in Enhanced Expression of the Virulence Gene <i>lctP</i> Frequently Possess a <i>mtrR</i> Promoter Mutation That Decreases Antibiotic Susceptibility. MBio, 2022, 13, e0027622.	4.1	4
357	Is the end of gonorrhoea in sight?. Lancet Infectious Diseases, The, 2022, 22, 919-921.	9.1	4
358	A Single Amino Acid Substitution in Elongation Factor G Can Confer Low-Level Gentamicin Resistance in <i>Neisseria gonorrhoeae</i> . Antimicrobial Agents and Chemotherapy, 2022, 66, e0025122.	3.2	4
359	Prevalence, phenotypic and genetic characteristics of prolyliminopeptidase-negative <i>Neisseria gonorrhoeae</i> isolates in Sweden during 2000–2007. Apmis, 2009, 117, 900-904.	2.0	3
360	Laboratory Diagnosis of Sexually Transmitted Infections in Belarus. Acta Dermato-Venereologica, 2011, 91, 64-65.	1.3	3

#	ARTICLE	IF	CITATIONS
361	Reply to "Management of Pharyngeal Gonorrhoea Is Crucial To Prevent the Emergence and Spread of Antibiotic-Resistant <i>Neisseria gonorrhoeae</i> " Antimicrobial Agents and Chemotherapy, 2012, 56, 4041-4042.	3.2	3
362	2012 European guideline on the diagnosis and treatment of gonorrhoea in adults*. Przegląd Dermatologiczny, 2014, 2, 168-178.	0.1	3
363	Analytical specificity and sensitivity of the novel dual-target GeneProof <i>Neisseria gonorrhoeae</i> PCR kit for detection of <i>N. gonorrhoeae</i> . Apmis, 2015, 123, 955-958.	2.0	3
364	Will Genome Analysis Elucidate Evolution, Global Transmission and Virulence of <i>Neisseria Meningitidis</i> Lineages?. EBioMedicine, 2015, 2, 186-187.	6.1	3
365	Collecting and exploiting data to understand a nation's sexual health needs: Implications for the British National Surveys of Sexual Attitudes and Lifestyles (Natsal). Sexually Transmitted Infections, 2019, 95, 159-161.	1.9	3
366	High in vitro activity of DIS-73285, a novel antimicrobial with a new mechanism of action, against MDR and XDR <i>Neisseria gonorrhoeae</i> . Journal of Antimicrobial Chemotherapy, 2020, 75, 3244-3247.	3.0	3
367	O01.8...Contemporary syphilis is characterised by rapid global spread of pandemic <i>Treponema pallidum</i> lineages. , 2021, , .		3
368	Lack of diagnostic-escape mutants of group B streptococcus in Slovenia. Clinical Microbiology and Infection, 2021, 27, 1054-1055.	6.0	3
369	Serum Complement Activation by C4BP-IgM Fusion Protein Can Restore Susceptibility to Antibiotics in <i>Neisseria gonorrhoeae</i> . Frontiers in Immunology, 2021, 12, 726801.	4.8	3
370	No widespread dissemination of <i>Chlamydia trachomatis</i> diagnostic-escape variants and the impact of <i>Neisseria gonorrhoeae</i> positivity on the Aptima Combo 2 assay. Sexually Transmitted Infections, 2022, 98, 366-370.	1.9	3
371	Validation of an Aptima-format Finnish new variant of <i>Chlamydia trachomatis</i> (FI-nvCT) surveillance assay, 2019. Eurosurveillance, 2020, 25, .	7.0	3
372	First reported lymphogranuloma venereum cases in Russia discovered in men who have sex with men attending proctologists. International Journal of STD and AIDS, 2022, , 095646242110727.	1.1	3
373	Performance of the first commercial dual resistance assay, AmpliSens <i>Mycoplasma genitalium</i> -ML/FQ-Resist-FL, for detection of potential macrolide and quinolone resistance-associated mutations and prevalence of <i>M. genitalium</i> resistance mutations in St. Petersburg, Russia. Sexually Transmitted Infections. 0. , sextrans-2021-055249.	1.9	3
374	O21.3...Fitness Studies on <i>Neisseria Gonorrhoeae</i> Harboring Mosaic penA Alleles from Ceftriaxone-Resistant Isolates Predict the Spread of Resistance to Extended-Spectrum Cephalosporins. Sexually Transmitted Infections, 2013, 89, A67.2-A67.	1.9	2
375	In vitro activity of the ketolide cethromycin in multidrug-resistant clinical <i>Neisseria gonorrhoeae</i> isolates and international reference strains. Journal of Chemotherapy, 2019, 31, 246-251.	1.5	2
376	P601...Macrolide and fluoroquinolone resistance-associated mutations in <i>Mycoplasma genitalium</i> : a systematic review and meta-analysis. , 2019, , .		2
377	Optimizations to keep gonorrhoea treatable and reduce antimicrobial resistance selection. Nature Reviews Urology, 2020, 17, 609-610.	3.8	2
378	Antimicrobial susceptibility of <i>Neisseria gonorrhoeae</i> isolates and syndromic treatment of men with urethral discharge in Kingston, Jamaica, 2018-19. Journal of Antimicrobial Chemotherapy, 2021, , .	3.0	2

#	ARTICLE	IF	CITATIONS
379	The "2014 European guideline on the management of syphilis"™ has now been published. <i>Eurosurveillance</i> , 2014, 19, 20957.	7.0	2
380	Clinical and epidemiological characteristics of males with syphilis in Białystok, Poland in 2008-2013. <i>Przegląd Epidemiologiczny</i> , 2015, 69, 41-5, 143-6.	0.2	2
381	Syphilis in females in Białystok, Poland, 2000-2015. <i>Przegląd Epidemiologiczny</i> , 2016, 70, 273-280.	0.2	2
382	OUP accepted manuscript. <i>Journal of Antimicrobial Chemotherapy</i> , 2022, , .	3.0	2
383	S15.2 European gonococcal antimicrobial surveillance programme (Euro-GASP): towards timelier monitoring. <i>Sexually Transmitted Infections</i> , 2011, 87, A19-A19.	1.9	1
384	O03.1"Risk Factors For Antimicrobial Resistant <i>Neisseria Gonorrhoeae</i> in Europe: Abstract O03.1 Table 1. <i>Sexually Transmitted Infections</i> , 2013, 89, A30.2-A30.	1.9	1
385	P5.077"Nucleic Acid Amplification Test (NAAT) Diagnostics Combined with Delayed <i>Neisseria Gonorrhoeae</i> Cultivation of NAAT Positive Samples Using the ESwab,® System - the Solution For Future Gonococcal Antimicrobial Susceptibility Surveillance?. <i>Sexually Transmitted Infections</i> , 2013, 89, A358.3-A359.	1.9	1
386	P3.157"Does the european gonococcal antimicrobial surveillance programme (EURO-GASP) accurately reflect the true antimicrobial resistance situation in europe?. , 2017, , .		1
387	Now Is the Time to Implement Whole Genome Sequencing in the Global Antimicrobial Resistance Surveillance for <i>Neisseria gonorrhoeae</i> ?. <i>EClinicalMedicine</i> , 2019, 7, 11-12.	7.1	1
388	Author's reply: The Russian gonococcal antimicrobial susceptibility programme (RU-GASP)--national resistance prevalence in 2007 and 2008, and trends during 2005-2008. <i>Eurosurveillance</i> , 2010, 15, .	7.0	1
389	Quality enhancements of laboratory diagnosis of sexually transmitted infections in Russia. <i>International Journal of STD and AIDS</i> , 2009, 20, 292-294.	1.1	0
390	P3-S1.22 Evaluation of performance of six commercial assays for detection of characterised isolates of <i>Neisseria gonorrhoeae</i> and other <i>Neisseria</i> spp.. <i>Sexually Transmitted Infections</i> , 2011, 87, A274-A275.	1.9	0
391	O1-S03.03 Clonally related <i>Neisseria gonorrhoeae</i> isolates with decreased susceptibility to extended-spectrum cephalosporins in Amsterdam, the Netherlands. <i>Sexually Transmitted Infections</i> , 2011, 87, A26-A27.	1.9	0
392	P1.019"Identification of the Amino Acids Conferring High-Level Resistance to Expanded-Spectrum Cephalosporins in the <i>penA</i> Gene from the <i>Neisseria Gonorrhoeae</i> Strain H041. <i>Sexually Transmitted Infections</i> , 2013, 89, A79.2-A79.	1.9	0
393	P3.152"Prevalence of <i>Neisseria Gonorrhoeae</i> Infection in Two Distinct Men-Who-Have-Sex-With-Men (MSM) Populations in Slovenia in 2012. <i>Sexually Transmitted Infections</i> , 2013, 89, A195.1-A195.	1.9	0
394	P3.292"The 2013 IUSTI European Collaborative Clinical Group (ECCG) Report on the Diagnosis and Management of Chlamydial Infections in Europe. <i>Sexually Transmitted Infections</i> , 2013, 89, A240.1-A240.	1.9	0
395	P1.018"Analysis of Mosaic Penicillin-Binding Protein 2 Variants with Ala501 Mutations That Confer High-Level Resistance to Expanded-Spectrum Cephalosporins in <i>Neisseria Gonorrhoeae</i> . <i>Sexually Transmitted Infections</i> , 2013, 89, A79.1-A79.	1.9	0
396	P5.081"Analytical Evaluation of the GeneXpert® CT/NG, the First Genetic Point of Care Assay For Simultaneous Detection of <i>Neisseria Gonorrhoeae</i> and <i>Chlamydia Trachomatis</i> . <i>Sexually Transmitted Infections</i> , 2013, 89, A360.1-A360.	1.9	0

#	ARTICLE	IF	CITATIONS
397	Second European Multi-Disciplinary Conference of National Strategies for Chlamydia Trachomatis and Human Papillomavirus (NSCP Conference) in Berlin, 2013 – Enhanced Detection, Management and Surveillance of Sexually Transmitted Infections in Europe are Essential!. <i>International Journal of Immunopathology and Pharmacology</i> , 2013, 26, 839-845.	2.1	0
398	P5.064 – Preliminary Analytical Evaluation of Artus® CT/NG, For Simultaneous Detection of Neisseria Gonorrhoeae and Chlamydia Trachomatis. <i>Sexually Transmitted Infections</i> , 2013, 89, A354.3-A355.	1.9	0
399	P1.020 – Phenotypic and Genetic Characterization of the First Three Cases of Extended-Spectrum Cephalosporin Resistant <i>Neisseria Gonorrhoeae</i> Infection in South Africa and Association with Cefixime Treatment Failure. <i>Sexually Transmitted Infections</i> , 2013, 89, A79.3-A80.	1.9	0
400	Holistic actions are essential to combat the global public health burden of non-viral sexually transmitted infections: challenges and future perspectives. <i>Expert Review of Anti-Infective Therapy</i> , 2014, 12, 649-651.	4.4	0
401	003.6 – Timing of test of cure for anogenital <i>neisseria gonorrhoeae</i> infections - a prospective cohort study using nucleic acid amplification tests. <i>Sexually Transmitted Infections</i> , 2015, 91, A32.1-A32.	1.9	0
402	006.2 – High in vitro susceptibility to the novel spiropyrimidinetrione azd0914 among 873 contemporary clinical <i>neisseria gonorrhoeae</i> isolates in 21 european countries during 2012–2014. <i>Sexually Transmitted Infections</i> , 2015, 91, A37.3-A38.	1.9	0
403	009.1 – Standardised, quality assured time-kill curve analysis and pharmacodynamic functions of different antibiotics for in vitro evaluation of treatment regimens for <i>neisseria gonorrhoeae</i> . <i>Sexually Transmitted Infections</i> , 2015, 91, A44.3-A45.	1.9	0
404	009.2 – Establishment of the gonorrhoea mouse model for pre-clinical testing of antimicrobial agents against <i>neisseria gonorrhoeae</i> . <i>Sexually Transmitted Infections</i> , 2015, 91, A45.1-A45.	1.9	0
405	P141 – A service evaluation for and on behalf of the European Clinical Collaborative Group (ECCG) - The management of Gonorrhoea across Europe. <i>Sexually Transmitted Infections</i> , 2016, 92, A68.3-A69.	1.9	0
406	O01.1 – A tale of two halves; low extended-spectrum cephalosporin and high azithromycin resistance in <i>neisseria gonorrhoeae</i> in europe, 2015. , 2017, , .		0
407	P1.59 – Genomic characterisation of urethritis-associated <i>neisseria meningitidis</i> . , 2017, , .		0
408	LB1.69 – Clinical and analytical evaluation of the new aptimamycoplasma genitalium assay on the panther instrument (HOLOGIC), m. genitalium prevalence, and antimicrobial resistance in m. genitalium in sweden, denmark and norway in 2016. , 2017, , .		0
409	P350 – What is the optimum method for collecting robust data to understand a nation's sexual health needs?. , 2019, , .		0
410	P637 – <i>Neisseria gonorrhoeae</i> genomic diversity in high risk groups in switzerland. , 2019, , .		0
411	P673 – In-vitro activity of SMT-571 and comparators against clinical isolates and reference strains of <i>neisseria gonorrhoeae</i> . , 2019, , .		0
412	'Gentamicin 240 mg plus azithromycin 2 g vs. ceftriaxone 500 mg plus azithromycin 2 g for treatment of rectal and pharyngeal gonorrhoea' – Author's reply. <i>Clinical Microbiology and Infection</i> , 2020, 26, 799-800.	6.0	0
413	Late-stage parenchymatous neurosyphilis presenting as general paresis of insane, Poland – case report. <i>Przegląd Epidemiologiczny</i> , 2016, 70, 585-592.	0.2	0
414	The '2015 European guideline on the management of Chlamydia trachomatis infections' has now been published. <i>Eurosurveillance</i> , 2015, 20, 30080.	7.0	0



#	ARTICLE	IF	CITATIONS
415	Unencapsulated penicillin-resistant <i>Neisseria meningitidis</i> ST-53 clonal complex strain causing symptomatic proctitis in an HIV-negative man who has sex with men: A case report. International Journal of STD and AIDS, 0, , 095646242211136.	1.1	0